ArticleThe Journal of biological chemistry2014
Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation.
Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.Medicine · 2017Pooled it
- MDSCs in Breast Cancer: Metastasis, Lipid Metabolism, and Therapeutics.Molecular cancer research : MCR · 2025Review
- Updating the Pharmacological Effects of α-Mangostin Compound and Unraveling Its Mechanism of Action: A Computational Study Review.Drug design, development and therapy · 2024Review
- CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.iScience · 2021Article
- Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF-κB/COX-2 signalling pathway.IET nanobiotechnology · 2020Article
- Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.Melanoma research · 2019Article
- Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection.Science advances · 2019Article
- A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.International journal of cancer · 2018Review
- Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.Oncology letters · 2018Article
- Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.Journal of cancer research and clinical oncology · 2018Article
- Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.International journal of molecular sciences · 2018Review
- Interleukin-6Frontiers in immunology · 2017Article
- Inflammasomes in Inflammation-Induced Cancer.Frontiers in immunology · 2017Review
- Age-associated impairment of antitumor immunity in carcinoma-bearing mice and restoration by oral administration of Lentinula edodes mycelia extract.Cancer immunology, immunotherapy : CII · 2016Article
- Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Gambogic acid induces apoptosis and inhibits colorectal tumor growth via mitochondrial pathways.World journal of gastroenterology · 2015Article
- Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- Article
- Microbiome, inflammation, and cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
- Expression of concern · 2020-06-26Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Updated to Retraction ·
- Retraction · 2021-04-29Duplication of/in Image · Investigation by Journal/Publisher · Manipulation of Images · Original Data and/or Images not Provided and/or not Available · Upgrade/Update of Prior Notice(s) ·
- Expression of concern
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanisms for cancer-related inflammation remain to be fully elucidated. Non-apoptotic functions of Fas signaling have been proposed to play an important role in promoting tumor progression. It has yet to be determined if targeting Fas signaling can control tumor progression through suppression of cancer-related inflammation. In the current study we found that breast cancer cells with constitutive Fas expression were resistant to apoptosis induction by agonistic anti-Fas antibody (Jo2) ligation or Fas ligand cross-linking. Higher expression of Fas in human breast cancer tissue has been significantly correlated with poorer prognosis in breast cancer patients. To determine whether blockade of Fas signaling in breast cancer could suppress tumor progression, we prepared an orthotopic xenograft mouse model with mammary cancer cells 4T1 and found that blockade of Fas signaling in 4T1 cancer cells markedly reduced tumor growth, inhibited tumor metastasis in vivo, and prolonged survival of tumor-bearing mice. Mechanistically, blockade of Fas signaling in cancer cells significantly decreased systemic or local recruitment of myeloid derived suppressor cells (MDSCs) in vivo. Furthermore, blockade of Fas signaling markedly reduced IL-6, prostaglandin E2 production from breast cancer cells by impairing p-p38, and activity of the NFκB pathway. In addition, administration of a COX-2 inhibitor and anti-IL-6 antibody significantly reduced MDSC accumulation in vivo. Therefore, blockade of Fas signaling can suppress breast cancer progression by inhibiting proinflammatory cytokine production and MDSC accumulation, indicating that Fas signaling-initiated cancer-related inflammation in breast cancer cells may be a potential target for treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.